Bruker Corporation
General ticker "BRKR" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $6.1B (TTM average)
Bruker Corporation follows the US Stock Market performance with the rate: 46.2%.
Estimated limits based on current volatility of 2.7%: low 52.85$, high 55.76$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-03-23, amount 0.05$ (Y0.37%)
- Total employees count: 11085 (-2.7%) as of 2025
- China accounted for 14.0% of revenue in the fiscal year ended 2024-12-31
- US accounted for 27.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Geopolitical risks, Economic downturns and volatility, Cybersecurity threats, Liquidity and credit risks
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [36.26$, 59.65$]
- 2026-12-31 to 2027-12-31 estimated range: [37.60$, 61.63$]
Financial Metrics affecting the BRKR estimates:
- Negative: with PPE of 23.8 at the end of fiscal year the price was very high
- Positive: -5.39 < Operating profit margin, % of 1.98
- Positive: Inventory ratio change, % of 0.22 <= 0.78
- Positive: Industry inventory ratio change (median), % of -0.30 <= -0.16
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: -0.02 < Operating cash flow per share per price, % of 1.87
- Positive: -3.75 < Return on assets ratio (scaled to [-100,100]) of -0.12
- Negative: negative Industry operating cash flow (median)
- Positive: 19.24 < Shareholder equity ratio, % of 39.36 <= 42.59
Short-term BRKR quotes
Long-term BRKR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,964.50MM | $3,366.40MM | $3,436.50MM |
| Operating Expenses | $2,527.60MM | $3,113.30MM | $3,368.30MM |
| Operating Income | $436.90MM | $253.10MM | $68.20MM |
| Non-Operating Income | $107.30MM | $-46.20MM | $-46.20MM |
| R&D Expense | $294.80MM | $376.50MM | $395.20MM |
| Income(Loss) | $544.20MM | $206.90MM | $22.00MM |
| Taxes | $117.70MM | $91.40MM | $29.30MM |
| Other Income(Loss) | $2.00MM | $-1.70MM | $-1.00MM |
| Net Income(Loss)* | $427.20MM | $113.10MM | $-8.60MM |
| Stockholders Equity | $1,377.20MM | $1,781.20MM | $2,456.50MM |
| Inventory | $968.30MM | $1,067.80MM | $1,094.60MM |
| Assets | $4,249.90MM | $5,806.70MM | $6,241.40MM |
| Operating Cash Flow | $350.10MM | $251.30MM | $134.10MM |
| Capital expenditure | $106.90MM | $115.30MM | $90.80MM |
| Investing Cash Flow | $-326.00MM | $-1,757.30MM | $-196.50MM |
| Financing Cash Flow | $-193.40MM | $1,229.80MM | $135.10MM |
| Earnings Per Share** | $2.92 | $0.76 | $-0.06 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.